Is There a Role for Cancer-Directed Surgery in Early-Stage Sarcomatoid or Biphasic Mesothelioma? Samuel Kim, MD, David A. Bull, MD, Linda Garland, MD, Zain Khalpey, MD, PhD, Baldasarre Stea, MD, PhD, Sun Yi, MD, Charles C. Hsu, MD, PhD The Annals of Thoracic Surgery Volume 107, Issue 1, Pages 194-201 (January 2019) DOI: 10.1016/j.athoracsur.2018.07.081 Copyright © 2019 The Society of Thoracic Surgeons Terms and Conditions
Fig 1 Flow diagram of patient selection and propensity matching. (NOS = not otherwise specified.) The Annals of Thoracic Surgery 2019 107, 194-201DOI: (10.1016/j.athoracsur.2018.07.081) Copyright © 2019 The Society of Thoracic Surgeons Terms and Conditions
Fig 2 Overall survival of patients with sarcomatoid mesothelioma: (A) patients who did and did not undergo resection, and (B) patients who underwent resection versus those who received chemotherapy or radiotherapy (RT) or both, without resection. The Annals of Thoracic Surgery 2019 107, 194-201DOI: (10.1016/j.athoracsur.2018.07.081) Copyright © 2019 The Society of Thoracic Surgeons Terms and Conditions
Fig 3 Overall survival of patients with biphasic mesothelioma: (A) patients who did and did not undergo resection, and (B) patients who underwent resection versus those who received chemotherapy or radiotherapy (RT) or both, without resection. The Annals of Thoracic Surgery 2019 107, 194-201DOI: (10.1016/j.athoracsur.2018.07.081) Copyright © 2019 The Society of Thoracic Surgeons Terms and Conditions